Elevance Health Inc. (NYSE: ELV) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
397.52
+3.32+0.84%
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 17.52 | EPS (ttm) | 22.50 | Insider Own | 0.36% | Shs Outstand | 216.87M | Perf Week | 4.89% |
| Market Cap | 85.49B | Forward P/E | 13.30 | EPS next Y | 29.64 | Insider Trans | 0.19% | Shs Float | 216.41M | Perf Month | -6.23% |
| Enterprise Value | 106.30B | PEG | - | EPS next Q | 4.73 | Inst Own | - | Short Float | 2.78% | Perf Quarter | 5.71% |
| Income | 4.94B | P/S | 0.43 | EPS this Y | 20.60% | Inst Trans | - | Short Ratio | 3.43 | Perf Half Y | 18.65% |
| Sales | 201.10B | P/B | 1.91 | EPS next Y | 9.22% | ROA | 3.93% | Short Interest | 6.03M | Perf YTD | 12.45% |
| Book/sh | - | P/C | 11.51 | EPS next 5Y | 15.26% | ROE | 11.24% | 52W High | 439.93 -9.64% | Perf Year | 42.67% |
| Cash/sh | - | P/FCF | 13.59 | EPS past 3/5Y | 1.14% 6.92% | ROIC | 7.22% | 52W Low | 277.15 43.43% | Perf 3Y | -16.43% |
| Dividend Est. | 6.88 (1.73%) | EV/EBITDA | 13.28 | Sales past 3/5Y | 8.34% 10.32% | Gross Margin | 38.95% | Volatility | 2.75% 3.14% | Perf 5Y | 2.65% |
| Dividend TTM | 6.86 (1.73%) | EV/Sales | 0.53 | EPS Y/Y TTM | -12.38% | Oper. Margin | 3.51% | ATR (14) | 12.36 | Perf 10Y | 196.61% |
| Dividend Ex-Date | Sep 10, 2026 | Quick Ratio | 1.52 | Sales Y/Y TTM | 13.75% | Profit Margin | 2.47% | RSI (14) | 53.06 | Recom | 2.29 |
| Dividend Gr. 3/5Y | 10.14% 12.47% | Current Ratio | 1.52 | EPS Q/Q | -15.72% | SMA20 | 1.86% | Beta | 0.69 | Target Price | 444.06 |
| Payout | 30.36% | Debt/Eq | 0.69 | Sales Q/Q | 1.40% | SMA50 | -0.50% | Rel Volume | 0.57 | Prev Close | 394.20 |
| Employees | 97,100 | LT Debt/Eq | 0.72 | Earnings | Oct 21 | SMA200 | 11.96% | Avg Volume | 1.65M | Price | 397.52 |
| IPO Date | Oct 30, 2001 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 19.94% 1.94% | Net Debt/EBITDA | 2.60 | Volume | 941,860 | Change | 0.84% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-17-26 | Reiterated | Leerink Partners | Market Perform | $364 → $395 |
| Jul-16-26 | Reiterated | Bernstein | Outperform | $482 → $488 |
| Jul-16-26 | Reiterated | New Street | $482 | |
| Jul-16-26 | Reiterated | Goldman Sachs | Buy | $370 → $395 |
| Jul-16-26 | Reiterated | Robert W. Baird | $331 → $393 | |
| Jul-16-26 | Reiterated | RBC Capital | Sector Perform | $439 → $424 |
| Jul-16-26 | Reiterated | Wells Fargo | Overweight | $492 → $473 |
| Jul-16-26 | Reiterated | Barclays | Overweight | $480 → $457 |
| Jul-16-26 | Reiterated | Guggenheim | Buy | $399 → $455 |
| Jul-14-26 | Reiterated | Truist Securities | Buy | $450 → $475 |
Latest News
Aug-04-26
Aug-01-26
Aug-01-2604:21AM
03:45AM
Jul-30-26
Jul-30-2612:00PM
Jul-29-26
03:47AM
Elevance Health, Inc. $ELV Shares Acquired by Amundidefenseworld.net
Jul-28-26
08:49AM
Jul-25-26
Jul-25-2611:30AM
Jul-24-26
Jul-24-2605:08AM
Jul-23-26
Jul-23-2602:29AM
Jul-22-26
Jul-22-2603:55AM
Jul-21-26
11:25AM
Artisan Value Fund Q2 2026 Portfolio Updateseekingalpha.com
Jul-20-26
Company
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 201,113 | 199,125 | 176,810 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 122,775 | 148,223 | 127,567 | — | — | — | — | — | — | |
| Gross Profit | 78,338 | 50,902 | 49,243 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 6,330 | 0 | 0 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 64,946 | 42,790 | 40,355 | — | — | — | — | — | — | |
| Operating Income | 7,062 | 8,112 | 8,888 | — | — | — | — | — | — | |
| Interest Expense | 1,130 | 1,402 | 1,185 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -70 | 0 | 201 | — | — | — | — | — | — | |
| Net Income Before Taxes | 5,862 | 6,710 | 7,904 | — | — | — | — | — | — | |
| Income Taxes | 915 | 1,049 | 1,933 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,963 | 5,662 | 5,980 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 4,947 | 5,661 | 5,971 | — | — | — | — | — | — | |
| Net Income | 4,963 | 5,662 | 5,980 | — | — | — | — | — | — | |
| EPS (Recurring) | 22.50 | 25.18 | 25.81 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 22.50 | 25.18 | 25.81 | — | — | — | — | — | — | |
| EPS (Diluted) | 22.50 | 25.12 | 25.68 | — | — | — | — | — | — | |
| EBITDA | 8,007 | 9,658 | 10,482 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 17.67 | 13.96 | 14.37 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.43 | 0.39 | 0.49 | — | — | — | — | — | — | |
| Gross Margin | 38.95 | 25.56 | 27.85 | — | — | — | — | — | — | |
| Operating Margin | 3.51 | 4.07 | 5.03 | — | — | — | — | — | — | |
| Net Margin | 2.47 | 2.84 | 3.38 | — | — | — | — | — | — | |
| Shares Outstanding | 218 | 222 | 233 | — | — | — | — | — | — | |
| Market Capitalization | 86,659 | 77,822 | 85,954 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BOUDREAUX GAIL | President and CEO | Jul 17 '26 | Buy | 367.79 | 2,725 | 1,002,230 | 171,976 | Jul 17 |
| PERU RAMIRO G | Director | Jul 17 '26 | Buy | 366.05 | 1,000 | 366,050 | 10,908 | Jul 17 |
| Penczek Ronald W | CAO & Controller | Jun 12 '26 | Sale | 403.16 | 369 | 148,766 | 3,740 | Jun 15 |
| Dixon Robert L JR | Director | Jun 11 '26 | Sale | 401.77 | 151 | 60,667 | 10,734 | Jun 12 |
| Penczek Ronald W | CAO & Controller | May 19 '26 | Option Exercise | 294.30 | 1,531 | 450,579 | 5,640 | May 20 |
| Penczek Ronald W | CAO & Controller | May 19 '26 | Sale | 403.13 | 1,531 | 617,192 | 4,109 | May 20 |
| SCHULMAN AMY W | Director | Mar 12 '26 | Sale | 287.50 | 26 | 7,475 | 218 | Mar 23 |
| Kendrick Charles Morgan JR | EVP & President, Commercial | Mar 06 '26 | Sale | 284.92 | 3,196 | 910,604 | 11,791 | Mar 09 |
| COLLIS STEVEN H | Director | Mar 05 '26 | Buy | 289.84 | 3,000 | 869,520 | 3,639 | Mar 06 |
| DeVore Susan D. | Director | Aug 19 '25 | Buy | 312.15 | 1,200 | 374,580 | 3,502 | Aug 21 |
| BOUDREAUX GAIL | President and CEO | Jul 18 '25 | Buy | 286.94 | 8,500 | 2,438,951 | 151,020 | Jul 18 |
| Kaye Mark | EVP & CFO | Apr 24 '25 | Sale | 424.82 | 4,588 | 1,949,074 | 18,977 | Apr 25 |
| Penczek Ronald W | CAO & Controller | Mar 10 '25 | Sale | 415.13 | 443 | 183,903 | 1,847 | Mar 11 |
| Kendrick Charles Morgan JR | EVP & President, Commercial | Mar 05 '25 | Sale | 396.30 | 3,504 | 1,388,635 | 10,116 | Mar 05 |
| Kendrick Charles Morgan JR | EVP & President, Commercial | Oct 18 '24 | Sale | 432.14 | 7,417 | 3,205,182 | 8,423 | Oct 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.